(Q53191850)

12 May 2018

title

Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen? (English)

1 reference

12 May 2018

author

Marius E. Mayerhoefer

1

1 reference

12 May 2018

Michael Weber

4

1 reference

12 May 2018

author name string

Matthias Schuetz

2

1 reference

12 May 2018

Silvia Magnaldi

3

1 reference

12 May 2018

Siegfried Trattnig

5

1 reference

12 May 2018

Georgios Karanikas

6

1 reference

12 May 2018

language of work or name

English

0 references

publication date

12 November 2011

1 reference

12 May 2018

published in

European Radiology

1 reference

12 May 2018

volume

22

1 reference

12 May 2018

issue

4

1 reference

12 May 2018

page(s)

938-946

1 reference

12 May 2018

https://scigraph.springernature.com/pub.10.1007/s00330-011-2328-7

exact match

0 references

cites work

Neuroendocrine tumors: current recommendations for diagnosis and surgical management

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

A systematic review of diagnostic procedures to detect midgut neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

The epidemiology of gastroenteropancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

Imaging of carcinoid tumors: spectrum of findings with pathologic and clinical correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

Standard imaging techniques for neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

(68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

Radiolabelling DOTA-peptides with 68Ga

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

A fully automated synthesis for the preparation of 68Ga-labelled peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

Iodinated contrast media and their adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

Is contrast material needed after treatment of malignant lymphoma in positron emission tomography/computed tomography?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2328-7

Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence

21 January 2018

1 reference

12 December 2020

A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract

1 reference

12 December 2020

Carcinoid metastases to the liver: role of triple-phase helical CT

1 reference

12 December 2020

PET/CT with 68Gallium-DOTA-peptides in NET: an overview

1 reference

12 December 2020

10.1007/S00330-011-2328-7

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018